Véronique Bruban

492 total citations
17 papers, 430 citations indexed

About

Véronique Bruban is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cell Biology. According to data from OpenAlex, Véronique Bruban has authored 17 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Cellular and Molecular Neuroscience and 3 papers in Cell Biology. Recurrent topics in Véronique Bruban's work include Receptor Mechanisms and Signaling (8 papers), Neurotransmitter Receptor Influence on Behavior (7 papers) and Pharmacological Receptor Mechanisms and Effects (5 papers). Véronique Bruban is often cited by papers focused on Receptor Mechanisms and Signaling (8 papers), Neurotransmitter Receptor Influence on Behavior (7 papers) and Pharmacological Receptor Mechanisms and Effects (5 papers). Véronique Bruban collaborates with scholars based in France, United States and Switzerland. Véronique Bruban's co-authors include Pascal Bousquet, Stéphan Schann, Josiane Feldman, Monique Dontenwill, Pierre Renard, Elizabeth Scalbert, Laurent Monassier, Bruno Pfeiffer, Philippe Boucher and Rachel L. Matz and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Nature Communications.

In The Last Decade

Véronique Bruban

17 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Véronique Bruban France 13 229 102 62 61 59 17 430
Chi‐Li Gong Taiwan 14 170 0.7× 55 0.5× 53 0.9× 41 0.7× 37 0.6× 38 451
Michael F. Ethier United States 11 179 0.8× 57 0.6× 87 1.4× 15 0.2× 32 0.5× 19 397
Rafika Jarray France 11 285 1.2× 90 0.9× 31 0.5× 47 0.8× 30 0.5× 14 455
G Laurent France 12 298 1.3× 76 0.7× 50 0.8× 31 0.5× 38 0.6× 47 471
Maurice Israël France 13 320 1.4× 128 1.3× 65 1.0× 13 0.2× 31 0.5× 27 587
Takashi Shimada Japan 10 149 0.7× 51 0.5× 20 0.3× 56 0.9× 75 1.3× 36 455
Sachie Asada Japan 11 305 1.3× 61 0.6× 111 1.8× 14 0.2× 38 0.6× 15 521
Akihiro Nezu Japan 13 329 1.4× 103 1.0× 56 0.9× 14 0.2× 18 0.3× 36 463
Fatemeh Derakhshan Canada 10 227 1.0× 29 0.3× 60 1.0× 16 0.3× 32 0.5× 23 634
Nicholas H. F. Fine United Kingdom 12 220 1.0× 93 0.9× 85 1.4× 18 0.3× 17 0.3× 16 520

Countries citing papers authored by Véronique Bruban

Since Specialization
Citations

This map shows the geographic impact of Véronique Bruban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Véronique Bruban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Véronique Bruban more than expected).

Fields of papers citing papers by Véronique Bruban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Véronique Bruban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Véronique Bruban. The network helps show where Véronique Bruban may publish in the future.

Co-authorship network of co-authors of Véronique Bruban

This figure shows the co-authorship network connecting the top 25 collaborators of Véronique Bruban. A scholar is included among the top collaborators of Véronique Bruban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Véronique Bruban. Véronique Bruban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Foppolo, Sophie, Véronique Bruban, Nelly Étienne-Selloum, et al.. (2021). Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. Cancers. 13(12). 3038–3038. 9 indexed citations
2.
Laquerrière, Patrice, Nelly Étienne-Selloum, Véronique Bruban, et al.. (2020). Biological Relevance of RGD‐Integrin Subtype‐Specific Ligands in Cancer. ChemBioChem. 22(7). 1151–1160. 48 indexed citations
3.
Terrand, Jérôme, Lionel Host, Rachel L. Matz, et al.. (2016). Convergent Signaling Pathways Controlled by LRP1 (Receptor-related Protein 1) Cytoplasmic and Extracellular Domains Limit Cellular Cholesterol Accumulation. Journal of Biological Chemistry. 291(10). 5116–5127. 34 indexed citations
4.
Host, Lionel, Sophie Martin, Nathalie Niederhoffer, et al.. (2014). The Src Homology and Collagen A (ShcA) Adaptor Protein Is Required for the Spatial Organization of the Costamere/Z-disk Network during Heart Development. Journal of Biological Chemistry. 290(4). 2419–2430. 5 indexed citations
5.
Schann, Stéphan, Monique Dontenwill, Laurent Monassier, et al.. (2012). Methylation of imidazoline related compounds leads to loss of α2-adrenoceptor affinity. Synthesis and biological evaluation of selective I1 imidazoline receptor ligands. Bioorganic & Medicinal Chemistry. 20(15). 4710–4715. 13 indexed citations
6.
Woldt, Estelle, Jérôme Terrand, Rachel L. Matz, et al.. (2012). The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nature Communications. 3(1). 1077–1077. 77 indexed citations
7.
Woldt, Estelle, Rachel L. Matz, Jérôme Terrand, et al.. (2011). Differential Signaling by Adaptor Molecules LRP1 and ShcA Regulates Adipogenesis by the Insulin-like Growth Factor-1 Receptor. Journal of Biological Chemistry. 286(19). 16775–16782. 24 indexed citations
8.
Bousquet, Pascal, et al.. (2003). I1 Imidazoline Receptors Involved in Cardiovascular Regulation: Where Are We and Where Are We Going?. Annals of the New York Academy of Sciences. 1009(1). 228–233. 25 indexed citations
9.
Schann, Stéphan, et al.. (2002). [125I]2-(2-Chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), a High-Affinity Radioligand Selective for I1Imidazoline Receptors. Molecular Pharmacology. 62(1). 181–191. 16 indexed citations
10.
Bruban, Véronique, Vanessa Estato, Stéphan Schann, et al.. (2002). Evidence for Synergy Between α 2 -Adrenergic and Nonadrenergic Mechanisms in Central Blood Pressure Regulation. Circulation. 105(9). 1116–1121. 24 indexed citations
11.
12.
Bruban, Véronique, et al.. (2001). Nitric Oxide and Central Antihypertensive Drugs. Hypertension. 37(2). 246–249. 11 indexed citations
13.
Bruban, Véronique, Josiane Feldman, Monique Dontenwill, et al.. (2001). Respective contributions of α‐adrenergic and non‐adrenergic mechanisms in the hypotensive effect of imidazoline‐like drugs. British Journal of Pharmacology. 133(2). 261–266. 36 indexed citations
14.
Bousquet, Pascal, Véronique Bruban, Stéphan Schann, & Josiane Feldman. (2000). Imidazoline receptors: a challenge. Pharmaceutica Acta Helvetiae. 74(2-3). 205–209. 21 indexed citations
15.
Bruban, Véronique, James A. Feldman, Monique Dontenwill, et al.. (1999). An Unexpected Central Hypertensive Effect of the New Imidazoline Compound Benazoline. Annals of the New York Academy of Sciences. 881(1). 102–105. 6 indexed citations
16.
Bousquet, Pascal, Véronique Bruban, Stéphan Schann, et al.. (1999). Participation of Imidazoline Receptors and Alpha2−‐Adrenoceptors in the Central Hypotensive Effects of Imidazoline‐Like Drugs. Annals of the New York Academy of Sciences. 881(1). 272–278. 12 indexed citations
17.
Feldman, Josiane, Laurent Monassier, Catherine Vonthron‐Sénécheau, et al.. (1998). Does a second generation of centrally acting antihypertensive drugs really exist?. Journal of the Autonomic Nervous System. 72(2-3). 94–97. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chi‐Li Gong Breakdown of academic impact, for papers by Michael F. Ethier Breakdown of academic impact, for papers by Rafika Jarray Breakdown of academic impact, for papers by G Laurent Breakdown of academic impact, for papers by Maurice Israël Breakdown of academic impact, for papers by Takashi Shimada Breakdown of academic impact, for papers by Sachie Asada Breakdown of academic impact, for papers by Akihiro Nezu Breakdown of academic impact, for papers by Fatemeh Derakhshan Breakdown of academic impact, for papers by Nicholas H. F. Fine
Rankless by CCL
2026